Maximum Daily Dose of Clavulanic Acid in Adults
The maximum daily dose of clavulanic acid for adults with normal renal function is 375 mg per day, typically administered as 125 mg three times daily with standard formulations, or 250 mg per day when using twice-daily extended-release formulations. 1
Standard Dosing Limits
The FDA-approved dosing regimens that define clavulanic acid limits are:
- Standard formulation: 500 mg amoxicillin/125 mg clavulanate every 8 hours = 375 mg clavulanate daily 1
- Extended-release formulation: 875 mg amoxicillin/125 mg clavulanate every 12 hours = 250 mg clavulanate daily 1
The 125 mg clavulanate dose per administration is fixed across all adult formulations due to tolerability concerns, particularly gastrointestinal side effects that increase with higher clavulanate doses. 2
Critical Dosing Principle
Clavulanic acid dose remains constant at 125 mg per tablet regardless of the amoxicillin dose (whether 250 mg, 500 mg, or 875 mg amoxicillin). 1 This fixed-dose strategy reflects the narrow therapeutic window of clavulanate—higher doses do not improve beta-lactamase inhibition but significantly increase adverse effects. 2
Pharmacokinetic Rationale
The 125 mg clavulanate limit per dose is based on:
- Elimination half-life: Approximately 1 hour in adults with normal renal function 3
- Urinary excretion: Only 27-28% of administered clavulanate is recovered unchanged in urine within 6 hours 3
- Non-renal clearance: Substantial hepatic metabolism accounts for the majority of elimination 4
Renal Impairment Considerations
In moderate renal impairment (GFR ≈ 30-50 mL/min), the dosing interval extends to every 12 hours, effectively reducing total daily clavulanate exposure to 250 mg/day. 5 This adjustment is critical because:
- Clavulanate clearance decreases less dramatically than amoxicillin clearance as GFR declines 4
- The amoxicillin-to-clavulanate exposure ratio increases substantially in renal dysfunction (from 4.9:1 at GFR >75 mL/min to 14.7:1 in hemodialysis patients) 4
For severe renal impairment (GFR <30 mL/min), further dose reduction to 500 mg amoxicillin/125 mg clavulanate every 24 hours limits clavulanate to 125 mg daily. 5
Common Prescribing Pitfalls
Do not substitute 250 mg/125 mg tablets for 250 mg/62.5 mg chewable tablets—they contain different amounts of clavulanic acid and are not interchangeable. 1 The standard tablet delivers twice the clavulanate dose per administration.
Avoid exceeding 375 mg clavulanate daily in patients with normal renal function, as higher doses increase diarrhea risk without improving antimicrobial efficacy. 1, 2 The q12h regimen (875/125 mg) is associated with significantly less diarrhea than the q8h regimen (500/125 mg) despite similar total amoxicillin exposure. 1
Special Population Adjustments
- Elderly patients: Use standard adult dosing (maximum 375 mg clavulanate daily) but monitor closely for adverse effects, particularly diarrhea and hepatotoxicity 5
- Hepatic impairment: Dose with caution and monitor hepatic function regularly, though specific clavulanate dose reductions are not defined 1
- Critically ill patients on renal replacement therapy: Even with normal native kidney function, RRT significantly increases drug clearance—consider therapeutic drug monitoring and potentially higher doses (up to 2.2 g amoxicillin component 6-8 hourly, though this would still maintain clavulanate at standard doses per administration) 6